<DOC>
	<DOCNO>NCT00848601</DOCNO>
	<brief_summary>Patients hormone docetaxel refractory prostate cancer relapsed/refractory non-Hodgkin 's lymphoma available standard therapy therapy may provide clinical benefit available enrol . Primary objective : estimate maximum tolerate dose dose-limiting toxicity . Secondary objective : Response rate , pharmacokinetic pharmacodynamic profile , Prostate Specific Antigen response renal elimination .</brief_summary>
	<brief_title>Safety SGI-1776 , A PIM Kinase Inhibitor Refractory Prostate Cancer Relapsed/Refractory Non Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>General 1 . Read , understand sign IRB IECapproved ICF confirm willingness participate trial . 2 . At least 18 year old . 3 . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . 4 . Adequate bone marrow function ; normal renal hepatic function , normal cardiac function . 5 . Normal cardiac function opinion investigator support LVEF 50 % great screen echocardiogram ( MUGA ) , significant abnormality screen ECG ( eg , leave bundle branch block , III degree AV block , acute myocardial infarction , WolffParkinsonWhite syndrome QTc interval ≥ 450 msec ) history additional risk factor torsades de pointes ( eg , heart failure , hypokalemia family history Long QT Syndrome ) . 1 . Active secondary malignancy history malignancy within last two year except nonmelanoma skin cancer cervical carcinoma situ . 2 . History significant cardiovascular disease uncontrolled symptomatic arrhythmia , congestive heart failure and/or myocardial infarction Class 3 4 cardiac disease define New York Heart Association Functional Classification . 3 . Received anticancer agent ( ) within past 3 week , include investigational agent , chemotherapy ( 6 week nitrosoureas mitomycin ) , immunotherapy , biologic market investigational tyrosine kinase inhibitor . 4 . Received prior radiation therapy within past 4 week receive irradiation ≥ 25 % bone marrow reserve . 5 . Any serious , uncontrolled active infection require systemic treatment know infection HIV , HCV HBV . 6 . Symptomatic CNS metastasis lesion treatment require . Prostate Cancer 1 . Males histologically confirm adenocarcinoma prostate , metastatic ( e.g. , T , N , M1ac ) base bone scan , CT scan , MRI scan . Demonstrated evidence progressive disease despite androgen deprivation ( androgen ablation surgical castration ) , antiandrogen withdrawal progression disease docetaxelbased therapy . 2 . Demonstrated evidence progressive disease despite androgen deprivation ( androgen ablation surgical castration ) , antiandrogen withdrawal progression disease docetaxelbased therapy . • Greater 25 % increase 3 consecutive test ( PSA 1 &lt; PSA 2 &lt; PSA 3 ) , PSA value separate least 1 week 3 . Serum testosterone level ≤ 50 ng/dL post orchiectomy maintain continuous intermittent medical androgen suppression LHRH agonist antagonist . 4 . At least 4 week since prior flutamide , megestrol , ketoconazole , aminoglutethimide ; least 6 week since prior bicalutamide nilutamide . 5 . Systemic corticosteroid discontinue within two week dose , except low dose regimen may continue unchanged 6 . Strontium89 Samarium153 must complete least 8 week prior first dose therapy recover treatmentrelated toxicity . 1 . Must receive concurrent antiandrogen hormonal therapy hormone refractory prostate cancer . NonHodgkin 's Lymphoma 1 . Histologically proven relapsed refractory nonHodgkin 's lymphoma subject available standard therapy therapy may provide clinical benefit . 2 . Measurable disease ( least 1 lesion ≥ 1.5 cm ) . 1 . Bulky disease CT , define single mass &gt; 10 cm great diameter . 2 . Systemic corticosteroid within 2 week , except low dose regimen may continue unchanged . 3 . Received radiopharmaceutical therapy within past six week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>SGI-1776</keyword>
	<keyword>PIM</keyword>
	<keyword>Hormone &amp; Docetaxel refractory Prostate Cancer</keyword>
	<keyword>Refractory non-Hodgkin 's Lymphoma</keyword>
</DOC>